Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

PHASE3TerminatedINTERVENTIONAL
Enrollment

8,910

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
ObesityOverweight
Interventions
DRUG

NB32

Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.

DRUG

PBO

Placebo. Administered in addition to the weight management program.

BEHAVIORAL

Weight Management Program

A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.

Trial Locations (224)

Unknown

Birmingham

Dothan

Mobile

Scottsboro

Chandler

Mesa

Peoria

Phoenix

Scottsdale

Tucson

Tuscson

Little Rock

Anaheim

Carmichael

Escondido

Fresno

Harbor City

Huntington Beach

La Jolla

Lomita

Los Angeles

Paramount

Pasadena

Riverside

Sacramento

Santa Rosa

Spring Valley

Thousand Oaks

Torrance

West Hills

Colorado Springs

Denver

Golden

Wheat Ridge

Norwalk

Stamford

Wilmington

Washington D.C.

Boynton Beach

Brooksville

Clearwater

DeLand

Delray Beach

Gainesville

Jacksonville

Jacksonville Beach

Melbourne

Miami

New Port Richey

New Smyrna Beach

Oakland Park

Orlando

Palm Harbor

Pembroke Pines

Pensacola

Pinellas Park

St. Petersburg

Vero Beach

Wellington

Winter Haven

Atlanta

Austell

Columbus

Lawrenceville

Riverdale

Savannah

Stockbridge

Honolulu

Meridian

Chicago

Gurnee

Melrose Park

Bloomington

Brownsburg

Elwood

Evansville

Hammond

South Bend

Valparaiso

Ames

Council Bluffs

Des Moines

West Des Moines

Overland Park

Wichita

Crestview Hills

Louisville

Mount Sterling

Alexandria

Baton Rouge

Monroe

Natchitoches

Auburn

Bangor

Baltimore

Columbia

Elkridge

Lutherville

Salisbury

Boston

Brockton

Fall River

Haverhill

Methuen

Bingham Farms

Dearbon

Kalamazoo

Midland

Saginaw

Southfield

Stevensville

Edina

Rochester

Jackson

Olive Branch

Tupelo

St Louis

Butte

Missoula

Fremont

Grand Island

Omaha

Henderson

Las Vegas

Reno

Sparks

Belvidere

Edison

Elizabeth

Elmer

Linden

Ridgewood

Albuquerque

Endwell

New Hyde Park

New York

Staten Island

Syracuse

The Bronx

Williamsville

Cary

Charlotte

Durham

Elizabeth City

Greensboro

Greenville

Hickory

Morganton

Raleigh

Salisbury

Wilmington

Winston-Salem

Akron

Beachwood

Cincinnati

Cleveland

Columbus

Delaware

Kettering

Marion

Mentor

Willoughby Hills

Oklahoma City

Medford

Portland

Altoona

Bensalem

Danville

Duncansville

Ephrata

Jersey Shore

Lancaster

Lansdale

Norristown

Scottdale

Sellersville

State College

West Reading

Wilkes-Barre

Anderson

Charleston

Columbia

Greenville

Greer

Hodges

Laurens

Mt. Pleasant

Rapid City

Bristol

Chattanooga

Germantown

Jackson

Kingsport

Knoxville

Memphis

Beaumont

Corpus Christi

Dallas

Houston

Hurst

Lake Jackson

McKinney

San Antonio

Schertz

Tomball

Waco

Bountiful

Draper

Murray

Ogden

Orem

Salt Lake City

West Jordan

Alexandria

Norfolk

Richmond

Winchester

Seattle

Spokane

Tacoma

Walla Walla

Green Bay

Kenosha

Madison

Sponsors
All Listed Sponsors
lead

Orexigen Therapeutics, Inc

INDUSTRY